Vascular Aneurysm
Conditions
Keywords
Abdominal, Aorta, Aneurysm, Endovascular, Repair
Brief summary
The EASY post-market clinical follow-up study is undertaken to demonstrate safety and clinical performance of the E-tegra Stent Graft System used in endovascular treatment of infrarenal aortic aneurysm.
Detailed description
In this study, patients will be observed who receive an E-tegra Stent Graft for the treatment of infrarenal aortic aneurysm. The E-tegra Stent Graft will be implanted at the discretion of the treating physician. Participating physicians will provide their observations collected during routine care for patients they have decided to treat with the E-tegra stent graft. Informed consent of the patients to the use of their clinical records for study purposes will be obtained before their data will be collected in the post-market clinical follow-up study. All patients will be asked to complete questionaires focussing on the health status (HS) (SF-12) and Quality of Life (QoL) (WHOQOL-BREF). The period of data collection will be approximately 60 months from the date of intervention for each patient. Source document verification will be performed on 100% of the patients; data from all visits will be reviewed and verified against existing source documents. Complete DICOM image files of the CT scans as well as other imaging files (e.g. CEUS, MRT) will be sent to a CoreLab for independent second evaluation. There is no CoreLab screening before inclusion. All adverse events defined prior to study start, will be adjudicated by the Clinical Evaluation Committee (CEC).
Interventions
DEVICEEndovascular Repair
Endovascular repair of the infrarenal aorta using a AAA stent graft.
Sponsors
JOTEC GmbH
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 * Patient must have an infrarenal aortic aneurysm with diameter ≥ 50 mm in females and ≥ 55 mm in males, or infrarenal aortic aneurysm with 40-50 mm that has increased in size by ≥ 1 cm per year * Patient is elegible for treatment inside the instructions for use of the E-tegra Stent Graft System * Patient is able and willing to undergo follow-up imaging and examinations prior to discharge from the hospital, at 30 days and 12 months, and annually thereafter until 5 years follow-up * Patient understands and has signed the Informed Consent Form prior to intervention * Patient has a life expectancy of at least 5 years
Exclusion criteria
* Patient with severe calcification or thrombi in the proximal sealing zone * Patient with infectious aneurysm * Patient with inflammatory aneurysm * Patient with pseudoaneurysm * Patient with symptomatic aneurysm * Patient with ruptured or traumatic aneurysm * Patient with suprarenal, juxtarenal, or pararenal aneurysm * Patient with aortic dissection * Patient with a reversed conical neck that is defined as a \> 3 mm distal increase over a 15 mm length * Patient in which the E-tegra Stent Graft System is used in combination with proximal or distal extenders of another company. * Patient who is planned to be treated with an adjunctive aortic bare metal stent or a fenestrated stent graft * Patient who is planned to be treated with a chimney / chimneys in the renal or visceral vessels * Patient who is planned to be treated with an iliac branch device or parallel grafts in the iliac vessels * Patient with genetic connective tissue disease (e.g. Marfan syndrome or Ehlers-Danlos syndrome) * Patient with eGFR \< 45 ml/min/1.73 m2 before the intervention * Patient had or planned to have a major surgical or interventional procedure within 30 days before or 30 days after the planned implantation of the E-tegra Stent Graft System * Patient with other medical condition that may cause the patient to be non-compliant with the protocol, confound the results, or is associated with a limited life expectancy of less than five years (i.e. heart failure, active malignancy (progressive, stable or partial remission)) * Patient who has been enrolled in another active clinical trial that does not allow inclusion in this trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | 30-day | Rate of all-cause mortality |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Aneurysm-related mortality | 30-day, 12, 24, 36, 60 months | Rate of aneurysm-related mortality |
| Aneurysm rupture-related mortality | 30-day, 12, 24, 36, 60 months | Rate of aneurysm rupture-related mortality |
| Technical success | 24 hours | Rate of patients with device technical success |
| Clinical success | 12 months | Rate of patients with clinical success |
| Reintervention | 30-day, 12, 24, 36, 60 months | Rate of patients with any reintervention |
| Reintervention-free survival | 12 months | Rate of patients with reintervention-free survival |
| Primary limb patency | 30-day, 12, 24, 36, 60 months | Rate of patients with primary E-tegra Stent Graft limb patency |
| Secondary limb patency | 30-day, 12, 24, 36, 60 months | Rate of patients with secondary E-tegra Stent Graft limb patency |
| Stable aneurysm size | 12, 60 months | Rate of patients with stable aneurysm size |
| Decreasing aneurysm size | 12, 60 months | Rate of patients with decreasing aneurysm size on CTA scan (≤ 5 mm in maximum diameter) |
| Increasing aneurysm size | 12, 60 months | Rate of patients with aneurysm growth on CTA scan (≥ 5 mm in maximum diameter) |
| Major adverse events | 30-day, 12, 24, 36, 60 months | Rate of patients with major adverse events (aneurysm-related death, aneurysm rupture, new myocardial infarction requiring intervention (percutaneous transluminal coronary angioplasty, bypass), new disabling stroke (mRS ≥ 2), visceral ischemia (bowel ischemia with surgical/endovascular intervention or submission to ICU or bowel necrosis with surgical/endovascular intervention or submission to ICU), new hepatic infarction, new chronic (\> 90 days) renal insufficiency/renal failure requiring dialysis, new permanent (\> 30 days) paraplegia (modified Tarlov Scale ≤ 2), new permanent (\> 30 days) paraparesis (modified Tarlov Scale 3 or 4), lower limb ischemia (increase in Rutherford classification) |
| Mortality | 24 hours, 12, 24, 36, 60 months | Rate of all-cause mortality |
| Endoleak Type Ib | 12, 60 months | Rate of patients with Type Ib endoleak |
| Endoleak Type II | 12, 60 months | Rate of patients with Type II endoleak |
| Endoleak Type III | 12, 60 months | Rate of patients with Type III endoleak |
| Endoleak Type IV | 12, 60 months | Rate of patients with Type IV endoleak |
| Endoleak of unknown origin | 12, 60 months | Rate of patients with endoleak of unknown origin |
| Stent graft migration | 12, 60 months | Rate of patients with stent graft migration \> 10 mm |
| Dislodgement | 30-day, 12, 24, 36, 60 months | Rate of patients with stent graft dislodgement (full component separation) |
| Stent fracture | 12, 60 months | Rate of patients with stent fracture |
| Stent graft infection | 30-day, 12, 24, 36, 60 months | Rate of patients with stent graft infection |
| Health status | 6, 12, 48 to 60 months | Rate of patients with the same level of health status as prior to surgery |
| QoL | 6, 12, 48 to 60 months | Rate of patients with the same level of QoL as prior to surgery |
| Endoleak Type Ia | 12, 60 months | Rate of patients with Type Ia endoleak |
Countries
Netherlands
Outcome results
None listed